Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

GIP

03.02.2026

Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.

Search the archive

Browse by month